Effects of recombinant human growth hormone on remnant liver after hepatectomy in hepatocellular carcinoma with cirrhosis.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To explore the effects of recombinant human growth hormone (rhGH) on the remnant liver after hepatectomy in hepatocellular carcinoma with liver cirrhosis.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Twenty-four patients with hepatocellular carcinoma who underwent hepatectomy were randomly divided into 2 groups: parenteral nutrition (PN) group (n=12) and rhGH+PN group (n=12).

Albumin (ALB) mRNA in liver biopsy specimens was detected by RT-PCR at post-operative d 6.

How the Study Was Run

The design is described as randomized.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Liver function, blood glucose, AFP, serum prealbumin and transferrin were detected before operation, at post-operative d 1 and d 6.

What Was Measured

Topics PubMed links to this paper include Albumins, Blood Glucose, Carcinoma, Hepatocellular, Hepatectomy, Human Growth Hormone, Ki-67 Antigen and Liver.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (World journal of gastroenterology), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.